A detailed history of Ubs Group Ag transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 7,691 shares of FHTX stock, worth $62,066. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,691
Previous 20,374 62.25%
Holding current value
$62,066
Previous $136,000 67.65%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$5.05 - $8.0 $64,049 - $101,464
-12,683 Reduced 62.25%
7,691 $44,000
Q1 2024

May 13, 2024

SELL
$2.82 - $7.94 $8,479 - $23,875
-3,007 Reduced 12.86%
20,374 $136,000
Q4 2023

Feb 09, 2024

BUY
$2.94 - $6.76 $38,058 - $87,508
12,945 Added 124.04%
23,381 $150,000
Q3 2023

Nov 09, 2023

SELL
$5.0 - $9.87 $9,475 - $18,703
-1,895 Reduced 15.37%
10,436 $52,000
Q2 2023

Aug 11, 2023

BUY
$5.37 - $8.84 $25,088 - $41,300
4,672 Added 61.0%
12,331 $86,000
Q1 2023

May 12, 2023

BUY
$4.66 - $8.99 $12,171 - $23,481
2,612 Added 51.75%
7,659 $47,000
Q4 2022

Feb 08, 2023

BUY
$5.44 - $9.46 $27,455 - $47,744
5,047 New
5,047 $32,000
Q2 2022

Aug 10, 2022

SELL
$8.48 - $16.84 $24,787 - $49,223
-2,923 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$8.87 - $22.1 $35,213 - $87,737
-3,970 Reduced 57.59%
2,923 $45,000
Q4 2021

Feb 14, 2022

BUY
$10.79 - $22.87 $74,375 - $157,642
6,893 New
6,893 $158,000
Q2 2021

Aug 13, 2021

SELL
$9.32 - $13.26 $19,907 - $28,323
-2,136 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$11.8 - $23.11 $1,321 - $2,588
-112 Reduced 4.98%
2,136 $28,000
Q4 2020

Feb 11, 2021

BUY
$15.12 - $25.88 $33,989 - $58,178
2,248 New
2,248 $46,000

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $336M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.